TechSeeker Profile

Adaptimmune Therapeutics PLC
Profile last edited on: 3/22/2022

Clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer
TS Type
Small Corp
Status
Active
Year Founded
2008
Last Involved Year
2015

Key People / Management

Location Information

60 Jubilee Avenue
Abingdon Ox14 4rx, GB
   (441) 235-430000
   www.adaptimmune.com

Public Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. to develop and commercialize allogeneic cell therapies to treat various oncology indications. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
UK
Employment
462
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
NASDAQ : ADAP
Received SBIR $$
No

Techseeker firm in the news

There are no news available.